Strong planning and evaluation has been critical for the development of the research infrastructure at the Hollings Cancer Center (HCC) and is carried out through multiple feed back mechanisms, both external and internal. The HCC External Scientific Advisory Board is the primary external mechanism for review and advice on the HCC's progress in research. Internal mechanisms include the advice and counsel of HCC's Senior Leaders who formally comprise the HCC Executive Council;the HCC Research Committee;an Internal Scientific Advisory Board that meets annually and is comprised of MUSC institutional leaders and officials;and a Clinical Research Oversight Committee. Other planning and evaluation efforts occur at the program and shared resource levels. In 2005, Dr. Kraft and the Senior Leadership developed a strategic road map to guide the HCC development over a five year period. This road map outlines nine strategic directions for research to be developed, the need for expanded services within existing shared research resources as well as new shared research resources, and organizational strategies to improve collaboration and interdisciplinary interactions. This road map is regularly re-visited, reviewed for progress and updated specifically with the input of new members of the Senior Leadership team as they have come on board.
The ongoing and clearly defined formative and summative evaluation and planning processes of the Hollings Cancer Center has been key to its growth in research in terms of extramural funding, enrollment onto clinical trials and dissemination of research results in the medical literature.
|Link, Laura A; Howley, Breege V; Hussey, George S et al. (2016) PCBP1/HNRNP E1 Protects Chromosomal Integrity by Translational Regulation of CDC27. Mol Cancer Res 14:634-46|
|Nelson, Michelle H; Bowers, Jacob S; Bailey, Stefanie R et al. (2016) Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning. J Immunother Cancer 4:6|
|Podbielska, Maria; Szulc, ZdzisÅ‚aw M; Kurowska, Ewa et al. (2016) Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line. J Lipid Res 57:2028-2039|
|Sambandam, Yuvaraj; Sakamuri, Sashank; Balasubramanian, Sundaravadivel et al. (2016) RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells. J Cell Biochem 117:118-25|
|Miller, Kayla; Dixit, Suraj; Bredlau, Amy-Lee et al. (2016) Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers. Nanomedicine (Lond) 11:581-95|
|Basher, Fahmin; Jeng, Emily K; Wong, Hing et al. (2016) Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC. Oncotarget 7:814-30|
|Small, James; Flanagan, Catherine; Armeson, Kent et al. (2016) Family history of cutaneous and noncutaneous malignancies in relation to the risk of keratinocyte carcinoma coupled with another type of cancer: A case-control study. J Am Acad Dermatol 75:1066-1068.e7|
|Maldonado, Eduardo N; DeHart, David N; Patnaik, Jyoti et al. (2016) ATP/ADP Turnover and Import of Glycolytic ATP into Mitochondria in Cancer Cells Is Independent of the Adenine Nucleotide Translocator. J Biol Chem 291:19642-50|
|Hendriks, Giel; Derr, Remco S; Misovic, Branislav et al. (2016) The Extended ToxTracker Assay Discriminates Between Induction of DNA Damage, Oxidative Stress, and Protein Misfolding. Toxicol Sci 150:190-203|
|Paul, Matt R; Levitt, Nicholas P; Moore, David E et al. (2016) Multivariate models from RNA-Seq SNVs yield candidate molecular targets for biomarker discovery: SNV-DA. BMC Genomics 17:263|
Showing the most recent 10 out of 311 publications